As the domestic market encounters a winter season, the medical industry is actively seeking breakthroughs, and going overseas has become a key pathway for companies to explore new incremental markets. In the past two years, many medical enterprises have gained more development opportunities by entering international markets, continuously strengthening their capabilities and driving ongoing innovation in the industry. However, on the flip side of these opportunities, challenges have always been present.
To build an international and professional exchange platform, gathering entrepreneurs and technicians in the medical field to jointly discuss the strategies, paths, and challenges of exporting original medical technologies. On the morning of May 8, 2024, byVCBeat,VB100 Collaborates with Boyuan CapitalThe "Medical Original Technology Going Overseas" sub-forum of the 8th Future Healthcare Ecosystem Exhibition was successfully held at the Convention and Exhibition Center, Beijing Yichuang International Convention and Exhibition Center Branch Venue 2.The conference was held inSenior IR Manager of Boyuan CapitalZhang NaiqianUnder the hosting, the forum entered the thematic speech session.Co-founder of Beijing Yanming Biotechnology Co., Ltd.,CEO Mr. Tianjing DengAs the first keynote speaker, Dr. Deng delivered a speech titled "The Current Status and Future Trends of China's Original Medical Technology Going Global." Drawing on his extensive industry experience, Dr. Deng provided an in-depth analysis of the current situation and challenges in new drug development, emphasizing the importance of original innovation in this field. He stressed that original innovation is the key driver of advancements in medical technology, while meeting clinical needs remains the ultimate goal of new drug development. He outlined four forms of Chinese companies going global: global product sales, international multicenter clinical trials, overseas financing, and international cooperation (including project sales, patent licensing, and joint research and development), underscoring the importance of clinical translation.
Deng Tianjing, Co-founder and CEO of Beijing Yanming Biotechnology Co., Ltd.Subsequently,Tao Feng, Founding Partner of Boyuan CapitalOn "Capital Empowering Innovative Technology to Go Global," he shared insights, analyzing the situation and opportunities for China's medical industry going global from a capital perspective. He first introduced Boyuan Capital as a professional investment fund focused on healthcare, which has successfully invested in over 100 companies in recent years, covering fields such as biopharmaceuticals and medical devices. Subsequently, Tao Feng elaborated on Boyuan Capital’s efforts in building an ecosystem and promoting industrial cooperation, with particular mention of deep collaborations with domestic and international industry players, as well as strategic partnerships with global medical device giants like Medtronic. He pointed out that as China's innovation capabilities improve, an increasing number of Chinese medical companies are gaining attention in the international market. Mr. Tao Feng believes that the future holds both opportunities and challenges for Chinese medical companies going global, requiring the power of capital to seize international market opportunities and achieve greater development.
Tao Feng, Founding Partner of Boyuan CapitalNext,Mr. Lai Lipeng, Co-founder and Chief Innovation Officer of XtalPiThe topic of the sharing session is "An Exploration Journey of AI + Experimental Robot-Driven Drug Development." He first shared the achievements of XtalPi in combining quantum physics, AI, and automated experimental technologies to build an innovative R&D platform, emphasizing that these technologies are crucial for driving innovation from scratch in multiple fields such as life sciences, new materials, agriculture, petrochemicals, and new energy. Next, he elaborated on how AI and experimental robots can accelerate the drug R&D process, improve R&D efficiency and success rates, and shared examples of how XtalPi utilizes these technologies to serve global partners. Mr. Lai Libo also mentioned the development trends in the global biopharmaceutical industry, especially the challenges in rare disease drug R&D, as well as the new opportunities brought by technological transformations like AI. Finally, he highlighted the importance of leveraging AI and experimental robot technologies to promote drug R&D in a globalized context and called for strengthened cooperation both within and outside the industry to jointly advance pharmaceutical technology.
Lai Lipeng, Co-founder and Chief Innovation Officer of XtalPi
Finally, the forum entered the roundtable discussion session, hosted byExecutive Director of Boyuan CapitalMr. Guo Jiacong, Beijing Yanming Biotechnology Co., Ltd.Co-founder,CEOMr. Deng Tianjing, SeekIn BioCo-founderMr. Li Zongwen, Beqi BiotechFounder of United SciencesMr. Liu Yiqi, Zhipptide BioCo-founderMr. Zhang Xujia and Xi Yuan An JianCo-founderMr. Yongcheng YingParticipate in Roundtable Discussion. The guests at the conference conducted an in-depth discussion on the theme of "how to bring innovative technology to the world stage," from theory to practice.Mr. Guo Jiachong, Executive Director of Boyuan CapitalFirst, he emphasized the importance of China's original technology in global promotion. He pointed out that, in the face of the adjustment cycle in China’s medical industry and competitive pressure from overseas markets, Chinese companies must actively seek breakthroughs in international markets.Co-founder of Beijing Yanming Biotechnology Co., Ltd.,CEO Mr. Tianjing DengStarting from innovative technologies in the field of cell pyroptosis, it explores how to drive industry development through scientific research achievements.Mr. Li Zongwen, Co-founder of SeekInShared the innovative application of single-cell sequencing technology and emphasized the crucial role of technological innovation in advancing the healthcare industry.Mr. Liu Yiqi, Co-Founder and Chief Scientific Officer of Beqi BioTaking the small molecule-induced pluripotent stem cell technology as an example, the path of combining scientific research with industry is illustrated.Founder and Chairman of Zhipet BioMr. Zhang Xujia, CEOFocuses on the development in the GLP1 field, sharing its company's innovative achievements and market prospects.Mr. Yongcheng Ying, Co-founder and Senior Vice President of Xi Yuan An JianStarting from innovative technologies in the field of pain management, the discussion emphasized the importance of focusing on patient needs and promoting the clinical application of technology. The key focus of the entire discussion was on the innovation and development of China's biomedicine technology and how to drive industry progress and expand into global markets through technological exports. The insights shared by the guests not only showcased the innovative achievements of their respective companies but also provided valuable experience and reflections on the internationalization of China's biomedicine technology.
Roundtable Discussion: How to Bring Innovative Technologies to the Global Stage
Secondly, byMr. Li Han, Executive Director of Boyuan CapitalThe second roundtable forum "Stories of Technology Going Global" was hosted, with the participating guests includingFounder and Chairman of Yizhun Intelligence&CEOMr. Lü Chenchong, HAIJIEYAPresidentMr. Fuliang Luo,Co-founder of Jiahua Pharma,CBOMs. Yun Xiao, Mr. Xiaoran Yu, Chief Operating Officer of Huapu Scientific Instruments, and Yuce BiotechCEO Mr. Yan Jiemin. The guests shared their insights and experiences respectively.Chenchong Lyu, Founder of Yizhun IntelligenceMr.Emphasized the industrialization prospects of medical imaging artificial intelligence, especially the breakthrough in ultrasound artificial intelligence, which will lead the industry's technological innovation.Haijieya President Luo FuliangMr.Introduced two innovative products registered both domestically and internationally, showcasing the pace of international development.Co-founder of Jiahua PharmaMr.Xiao YunFocuses on functional proteomics, providing new dimensional information for clinical and drug development through precision medicine and CRO services.Yu Xiaoran, Chief Operating Officer of Huapu Science and TechnologyMr.Proposed the development goal of scientific instruments for domestically produced alternatives, emphasizing technological breakthroughs in chromatography and related fields.Yuce BioCEO Yan JieminMr.Focused on the detection of biomarkers for neurodegenerative diseases, exploring more precise disease diagnosis methods through single-molecule technology pathways, and actively expanding overseas markets. Throughout the discussion, the guests unanimously agreed that the export of original medical technologies not only requires enterprises to possess strong technical capabilities and innovation abilities but also necessitates clear market positioning and international strategies. Meanwhile, they provided specific suggestions on how to strengthen international cooperation, promote technological innovation, and drive industrial upgrading.
Roundtable Discussion: The Ins and Outs of Technology Export
The successful hosting of this forum not only provided a platform for medical enterprises to exchange and cooperate but also injected new momentum into the international development of China's original medical technologies. In the future, with continuous technological advancements and market expansion, China's original medical technologies will play an increasingly important role in the international market. 
